Research progress on the effect of neutrophil elastase and its inhibitors in respiratory diseases
- PMID: 40579944
- PMCID: PMC12206257
- DOI: 10.1177/03000605251352789
Research progress on the effect of neutrophil elastase and its inhibitors in respiratory diseases
Abstract
Neutrophil elastase is a serine protease secreted by neutrophils that plays a crucial role in the onset and progression of various respiratory diseases. The imbalance between neutrophil elastase and its endogenous inhibitors can contribute to the onset and progression of respiratory diseases such as chronic obstructive pulmonary disease, cystic fibrosis, bronchiectasis, and acute respiratory distress syndrome. The excessive release of neutrophil elastase contributes to multiple pathophysiological processes, such as disruption of the alveolar-capillary barrier, oxidative stress and inflammatory responses, autophagy, and apoptosis. The use of neutrophil elastase as a biomarker in disease assessment and prognosis prediction as well as the potential of neutrophil elastase inhibitors in clinical treatment have shown broad application prospects. Neutrophil elastase inhibitors have certain limitations such as off-target effects, poor lung bioavailability, cost considerations, and variability in patient responses. This article reviews the literature on neutrophil elastase and its inhibitors in the field of respiratory diseases, aiming to provide new insights into the diagnosis and treatment of related respiratory diseases.
Keywords: Neutrophil elastase; endogenous neutrophil elastase inhibitors; neutrophil elastase inhibitors; respiratory diseases; synthetic neutrophil elastase inhibitors.
Conflict of interest statement
Declaration of conflicting interestsThe authors declare that there are no conflicts of interest.
Similar articles
-
Neutrophil elastase in bronchiectasis.Respir Res. 2017 Dec 19;18(1):211. doi: 10.1186/s12931-017-0691-x. Respir Res. 2017. PMID: 29258516 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics.Cell Commun Signal. 2023 Nov 2;21(1):314. doi: 10.1186/s12964-023-01337-4. Cell Commun Signal. 2023. PMID: 37919729 Free PMC article.
-
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x. Respir Res. 2024. PMID: 39709425 Free PMC article. Review.
-
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.Health Technol Assess. 2001;5(26):1-149. doi: 10.3310/hta5260. Health Technol Assess. 2001. PMID: 11701099
References
-
- Ocampo-Gallego JS, Pedroza-Escobar D, Caicedo-Ortega AR, et al. Human neutrophil elastase inhibitors: classification, biological-synthetic sources and their relevance in related diseases. Fundam Clin Pharmacol 2024; 38: 13–32. - PubMed
-
- AhYoung AP, Lin SJ, Gerhardy S, et al. An ancient mechanism of arginine-specific substrate cleavage: what's ‘up' with NSP4? Biochimie 2019; 166: 19–26. - PubMed
-
- Tsai YF, Hwang TL. Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010–2014). Expert Opin Ther Pat 2015; 25: 1145–1158. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources